CRISPR Therapeutics - CRSP Stock Forecast, Price & News

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Therapeutics Stock Down 7.7 %

CRSP Stock traded down $6.26 during trading on Tuesday, hitting $75.13. The company had a trading volume of 1,576,614 shares, compared to its average volume of 1,718,938. The firm has a market cap of $5.82 billion, a PE ratio of 21.12 and a beta of 1.93. CRISPR Therapeutics has a 1-year low of $42.51 and a 1-year high of $141.63. The firm has a 50-day moving average price of $71.10 and a 200-day moving average price of $63.21.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last released its earnings results on Monday, August 8th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.21) by ($0.19). CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter in the previous year, the firm posted $9.44 EPS. The business's revenue for the quarter was down 100.0% on a year-over-year basis. Sell-side analysts anticipate that CRISPR Therapeutics will post -8.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CRSP shares. SVB Leerink decreased their target price on CRISPR Therapeutics from $112.00 to $107.00 and set an "outperform" rating for the company in a report on Monday. Citigroup lifted their price target on CRISPR Therapeutics from $53.00 to $83.00 and gave the stock a "neutral" rating in a report on Tuesday, August 2nd. Piper Sandler lifted their price target on CRISPR Therapeutics from $115.00 to $121.00 and gave the stock an "overweight" rating in a report on Wednesday, June 22nd. Barclays downgraded CRISPR Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $99.00 to $88.00 in a report on Tuesday. Finally, Oppenheimer decreased their price target on CRISPR Therapeutics from $150.00 to $122.00 and set an "outperform" rating for the company in a report on Thursday, June 23rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $115.31.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the business's stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total transaction of $1,897,750.00. Following the transaction, the chief executive officer now owns 290,279 shares in the company, valued at approximately $22,035,078.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.70% of the stock is currently owned by insiders.